Latest Results

FY2020 2Q Consolidated Financial Overview

IFRS results

Revenues for the six months under review were ¥368.1 billion (an increase of 14.9% year on year), operating profit for the six months under review was ¥140.6 billion (an increase of 47.8% year on year), and net income for the six months under review was ¥102.3 billion (an increase of 47.6% year on year). These results include non-Core items, such as amortization of intangible assets of ¥0.7 billion, impairment loss of intangible assets of ¥0.1 billion and restructuring expenses of ¥2.3 billion, which are excluded from the Core results that Chugai adopts to manage recurring business activities.

Core results

Revenues for the six months under review were ¥368.1 billion (an increase of 14.9% year on year), due to increases both in overseas sales and royalties and other operating income.

Of revenues, sales were ¥305.7 billion (an increase of 8.3% year on year), due to an increase in export of Actemra® to Roche, including those for clinical trials for COVID-19 pneumonia, and the commencement of export of Hemlibra® to Roche at a regular shipment price. Royalties and other operating income amounted to ¥62.5 billion (an increase of 64.9% year on year), due to a large increase in royalties for Hemlibra® and its profit-sharing income as well as an increase in other operating income resulting from one-time income. Furthermore, cost to sales ratio was 42.9%, a 2.2 percentage point improvement year on year, due to a change in the product mix, etc. As a result, gross profit amounted to ¥236.9 billion (an increase of 22.9% year on year).

Operating expenses were ¥93.2 billion (an increase of 4.5% year on year). Marketing and distribution expenses were ¥32.3 billion (a decrease of 1.8% year on year), due to refraining from domestic business activities caused by the spread of COVID-19. Research and development expenses amounted to ¥52.9 billion (an increase of 10.4% year on year) due to an increase in expenses associated with the progress of projects, etc. General and administration expenses amounted to ¥8.0 billion (a decrease of 4.8% year on year) primarily due to a decrease in various expenses. As a result, Core operating profit was ¥143.7 billion (an increase of 38.8% year on year) and Core net income was ¥104.5 billion (an increase of 39.1% year on year).

Data is updated in real time. (Volume data is delayed about 20 minutes from actual transaction)

  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top